Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21
Design Therapeutics, Inc.
Design Therapeutics, Inc. DSGN | 0.00 |
Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:
DSGN) with a Outperform and raises the price target from $18 to $21.